Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 2 | Mind Blowing Facts

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

AbbVie Inc. (NYSE:ABBV) reported third-quarter 2025 sales of $15.78 billion on Friday, beating the consensus of $15.59 billion.

Benzinga

3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years

Here are three big pharma stocks that can reward patient investors with a proven history of stability, dividends, and long-term growth potential

MarketBeat

Qualcomm, Aptiv, Palo Alto And A Health Care Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades” on Tuesday, Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he is staying long on AbbVie Inc. (NYSE:ABBV).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

5 Dividend Kings For Generations Of Passive Income

These are five Dividend Kings, companies with 50+ years of dividend increases, covering recent developments, dividend safety, and valuation, so you can identify candidates for durable income that fit your goals.

Barchart

What to Expect From AbbVie's Q3 2025 Earnings Report

Pharma giant AbbVie is gearing up to announce its third-quarter results by the end of October, and analysts expect a high single-digit growth in earnings.

Barchart

Why AbbVie and Johnson & Johnson Could Outperform Pfizer

Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential

MarketBeat

3 Exceptional Stocks to Build Long-Term Wealth

Discover three standout growth stocks with strong long-term potential, spanning space, retail, and biotech industries, poised for sustained investor returns

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

AbbVie's Botox Shows Improvement In Movement Disorder Study

AbbVie Inc. (NYSE:ABBV) on Monday shared topline results from the Phase 2 ELATE trial evaluating onabotulinumtoxinA (BOTOX) compared to placebo for upper limb essential tremor.

Benzinga

AbbVie Stock Is Just What the Doctor Ordered

AbbVie (ABBV) stands out after its Allergan acquisition thanks to a transformed portfolio and higher long-term growth prospects. ABBV is trading at fresh all-time highs. Shares have a 100% Barchart “Buy” opinion and are trading above key moving averages. Analyst and investor sentiment is positive, with most major firms rating...

Barchart

3 Dividend Aristocrats Up 20%+ YTD With More Upside Ahead

These 3 buy-rated Dividend Aristocrats are up 20%+ YTD, and offer reliable dividends with more growth potential ahead.

Barchart

Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies

A U.S. federal judge has rejected challenges by two pharmaceutical manufacturers seeking to block a Maine law that regulates the use of contract pharmacies under the federal 340B drug discount program.

Benzinga

Should You Buy This Blue-Chip Dividend Stock at Record Highs?

AbbVie shares have hit record highs after extending Rinvoq’s patent protection to 2037, boosting confidence in future earnings and dividend growth, with analysts seeing steady fundamentals and modest upside as the company’s immunology pipeline drives results.

Barchart

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga

The 5 Best Dividend Stocks to Buy for Steady Income in 2025

Here are five “set-and-forget” dividend stocks.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why Is AbbVie Stock Trading Higher On Thursday?

AbbVie Inc. (NYSE:ABBV) stock is trading higher on Thursday following an SEC filing that settled litigation with all generic manufacturers, which filed abbreviated new drug applications with the U.S. Food and Drug Administration for generic versions of upadacitinib tablets, marketed by the company as Rinvoq.

Barchart

Is AbbVie Stock Underperforming the S&P 500?

AbbVie has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Barchart

These 2 Healthcare Stocks Are Even Better Bargain Buys Than UnitedHealth

As the healthcare sector lags broader markets, AbbVie’s innovation in immunology and Johnson & Johnson’s MedTech expansion make these dividend giants standout bargains at below-market valuations

MarketBeat

As the Market Rotates, This Healthcare ETF Is Leading the Way

Health care saw some of the worst losses this year. But as the calendar turned to August, it's been leading the market higher. This ETF provides exposure.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

AbbVie Strikes $1.2 Billion Agreement For Next-Gen Psychedelic Depression Treatment

AbbVie Inc. (NYSE:ABBV) announced Monday that it will acquire Gilgamesh Pharmaceuticals Inc.’s lead investigational candidate for moderate-to-severe major depressive disorder (MDD).

Benzinga

AbbVie's Patch Baldness Study Finds High Hair Coverage Rates With Investigational Drug Upadacitinib

AbbVie Inc. (NYSE:ABBV) on Thursday released topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (RINVOQ; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata (AA) with a mean…

Benzinga

AbbVie Inclusion In Medicare Drug Talks Fails To Justify Lawsuit, Court Rules

AbbVie Inc. (NYSE:ABBV), the manufacturer of Imbruvica, is at the center of a constitutional challenge to the federal government's new Drug Price Negotiation Program.

Barchart

AbbVie Stock Outlook: Is Wall Street Bullish or Bearish?

Despite AbbVie’s underperformance relative to the S&P 500 over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Benzinga

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion.

MarketBeat

AbbVie Stock Eyes Breakout as Pipeline and Profits Grow

AbbVie stock pops after strong Q2 earnings and raised guidance, as Skyrizi and Rinvoq offset Humira's decline and support a bullish outlook

Benzinga

AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.